Plinabulin Improves Survival in Asian Subset of EGFR Wild-Type NSCLC Patients

BeyondSpring's Phase 3 DUBLIN-3 trial showed Plinabulin + Docetaxel improving survival in a large Asian subset of EGFR wild-type NSCLC patients compared to Docetaxel alone. The combination achieved a statistically significant improvement in overall survival, with a hazard ratio of 0.81 and a median OS benefit of 2 months. Plinabulin also reduced severe neutropenia by 75%, positioning it as a late-stage candidate for a global registration path.